Prostate Cancer Reports


Volume 2 Number 6
 June 2014

Home > Prostate Cancer Reports > Volume 2 - Year 2014 > Number 6, June 2014

CONTENTS



Complications
Diagnosis and evaluation
Integrative medicine
Overall management
Recurrence
Treatment




Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA.
Risk of second primary tumors in men diagnosed with prostate cancer: A population-based cohort study.
Cancer. 2014 May 19. doi: 10.1002/cncr.28769. [Epub ahead of print]
Abstract | Related citations



Piccardo A, Paparo F, Picazzo R, Naseri M, Ricci P, Marziano A, Bacigalupo L, Biscaldi E, Rollandi GA, Grillo-Ruggieri F, Farsad M.
Value of Fused (18) F-Choline-PET/MRI to Evaluate Prostate Cancer Relapse in Patients Showing Biochemical Recurrence after EBRT: Preliminary Results.
Biomed Res Int. 2014;2014:103718. doi: 10.1155/2014/103718. Epub 2014 Apr 30.
Abstract | Full text | Related citations



Paroni R, Terraneo L, Bonomini F, Finati E, Virgili E, Bianciardi P, Favero G, Fraschini F, Reiter RJ, Rezzani R, Samaja M.
Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling.
J Pineal Res. 2014 May 1. doi: 10.1111/jpi.12142. [Epub ahead of print]
Abstract | Related citations



Guidelines

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M.
Prostate cancer, version 2.2014.
J Natl Compr Canc Netw. 2014 May;12(5):686-718. Epub 2014 Apr 1.
Abstract | Full text | Related citations


Meetings

Kapoor A.
What's new in prostate cancer research? Highlights of GU-ASCO 2014.
Can Urol Assoc J. 2014 Mar;8(3-4 Suppl 2):S8-S12.
Abstract | Full text | Related citations



Risk factors

Bonn SE, Wiklund F, Sjölander A, Szulkin R, Stattin P, Holmberg E, Grönberg H, Bälter K.
Body mass index and weight change in men with prostate cancer: progression and mortality.
Cancer Causes Control. 2014 May 9. [Epub ahead of print]
Abstract | Related citations


Risk groups

Huang CC, Kong MX, Zhou M, Rosenkrantz AB, Taneja SS, Melamed J, Deng FM.
Gleason Score 3 + 4=7 Prostate Cancer With Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Associated With Low-risk Tumor in Radical Prostatectomy Specimen.
Am J Surg Pathol. 2014 May 28. [Epub ahead of print]
Abstract | Related citations



Koulikov D, Mohler MC, Mehedint DC, Attwood K, Wilding GE, Mohler JL.
Low detectable PSA after radical prostatectomy: treat or watch?
J Urol. 2014 May 21. pii: S0022-5347(14)03620-9. doi: 10.1016/j.juro.2014.05.088. [Epub ahead of print]
Abstract | Related citations


Rose BS, Chen MH, Zhang D, Hirsch MS, Richie JP, Chang SL, Hegde JV, Loffredo MJ, D'Amico AV.
Maximum Tumor Diameter and the Risk of Prostate-Specific Antigen Recurrence After Radical Prostatectomy.
Clin Genitourin Cancer. 2014 Mar 28. pii: S1558-7673(14)00057-3. doi: 10.1016/j.clgc.2014.03.008. [Epub ahead of print]
Abstract | Related citations



First-line treatment

Localized PCa

Matsumoto K, Hagiwara M, Tanaka N, Hayakawa N, Ishida M, Ninomiya A, Nakajima Y, Nakamura S.
Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population.
Med Oncol. 2014 Jun;31(6):979. doi: 10.1007/s12032-014-0979-3. Epub 2014 Apr 30.
Abstract | Related citations


Treatment comparison

Localized PCa



Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Spångberg A, Andrén O, Palmgren J, Steineck G, Adami HO, Johansson JE.
Radical prostatectomy or watchful waiting in early prostate cancer.
N Engl J Med. 2014 Mar 6;370(10):932-42. doi: 10.1056/NEJMoa1311593.
Abstract | Full text | Related citations